Ulrica Slåne Bjerke has 30 years of experience as an investment professional. Prior to founding Arctic Aurora LifeScience in 2016 she successfully managed a biotech mandate at the Swedish pension fund AP3 for 10 years. Before joing AP3, Ulrica was a top-ranked sell-side healthcare analyst at leading Nordic investment banks including SEB Enskilda and Carnegie. Ulrica holds a MBASc from the Stockholm School of Economics, a CEFA and has studied medicine studies at Karolinska Institutet in Stockholm.
Topic: Capturing the value in healthcare innovation
Arctic Aurora LifeScience is a global equity fund with an investment focus on innovative pharmaceutical and biotechnology companies. Scientific advances that have helped us understand human biology and genetics, in addition to faster and more precis drug development capabilities, have led to fast growth and exciting prospects in this sector. The fund’s investments build on new and clearly differentiated therapies that answer to large and difficult unmet medical needs. The investment team has vast experience in the pharmaceutical industry and equity management, as well as genuine technical insights into the scientific and medical matter that surrounds biotechology investments. Arctic Aurora LifeScience is a part of Arctic Fund Management with offices in Oslo and Stockholm.